Short Interest in Kamada Ltd. (NASDAQ:KMDA) Expands By 61.8%

Kamada Ltd. (NASDAQ:KMDA) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 56,800 shares, a growth of 61.8% from the February 28th total of 35,100 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily volume of 210,800 shares, the days-to-cover ratio is currently 0.3 days.

Analysts Set New Price Targets

Several analysts recently issued reports on KMDA shares. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Kamada in a report on Thursday, March 6th. StockNews.com cut Kamada from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Finally, Benchmark started coverage on shares of Kamada in a report on Friday, March 21st. They issued a “buy” rating and a $15.00 price objective on the stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio bought a new position in Kamada in the 3rd quarter valued at about $77,000. JPMorgan Chase & Co. bought a new stake in shares of Kamada during the 4th quarter worth about $67,000. NewEdge Advisors LLC lifted its stake in shares of Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after acquiring an additional 8,260 shares during the period. Aristides Capital LLC boosted its holdings in shares of Kamada by 12.1% in the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 6,850 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after acquiring an additional 1,549 shares during the period. 20.38% of the stock is owned by institutional investors and hedge funds.

Kamada Price Performance

KMDA stock traded down $0.08 on Friday, reaching $6.75. The company’s stock had a trading volume of 49,625 shares, compared to its average volume of 79,188. Kamada has a 52 week low of $4.74 and a 52 week high of $9.16. The company has a market capitalization of $387.99 million, a P/E ratio of 24.11, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97. The firm has a fifty day moving average of $7.17 and a two-hundred day moving average of $6.30.

Kamada Dividend Announcement

The firm also recently declared a — dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be paid a $0.20 dividend. The ex-dividend date is Monday, March 17th.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.